Biogen (BIIB) vs BioNTech (BNTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Biogen (BIIB) has outperformed BioNTech (BNTX) over the past year, gaining 45.9% versus a loss of 10.2%. Over five years, BIIB leads with a -21.0% price change compared with -61.5% for BNTX. Biogen is the larger company by market cap ($32.06 billion vs $23.23 billion), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIIB | BNTX |
|---|---|---|
| Share price | $217.00 | $92.49 |
| Market cap | $32.06B | $23.23B |
| 1-day change | -2.32% | -2.90% |
| YTD return | +26.23% | +0.05% |
| 1-year return | +45.95% | -10.19% |
| 5-year return | -21.00% | -61.54% |
| P/E ratio (TTM) | 38.54 | — |
| Forward P/E | 13.14 | — |
| EPS (TTM) | $5.63 | $-7.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $9.89B | — |
| Revenue growth (YoY) | +2.22% | — |
| Net income (latest FY) | $1.29B | — |
| Gross margin | 75.69% | — |
| Net margin | 13.07% | — |
| 52-week high | $230.49 | $124.00 |
| 52-week low | $138.00 | $79.52 |
| Distance from 52-week high | -5.85% | -25.41% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +9.76% | +25.19% |
| Average volume | 1.07M | 1.15M |
| Shares outstanding | 147.75M | 251.20M |
| Employees | 7,500 | 7,807 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIIB has outperformed BNTX by 56.1 percentage points over the past year.
About Biogen
BIIB stock →Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,500 employees
About BioNTech
BNTX stock →BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees
BIIB vs BNTX FAQ
Which is bigger, Biogen or BioNTech?
Biogen (BIIB) is larger, with a market capitalization of $32.06B compared with $23.23B for BioNTech (BNTX).
Which stock has performed better over the past year, BIIB or BNTX?
BIIB returned +45.95% over the past 12 months, compared with -10.19% for BNTX (price return, excluding dividends). Past performance does not predict future results.
Are Biogen and BioNTech in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.